About Impel NeuroPharma
Impel NeuroPharma is a company based in Seattle (United States) founded in 2008. Impel NeuroPharma has raised $126.83 million across 19 funding rounds from investors including KKR, NIH and Norwest Venture Partners. The company has 158 employees. Impel NeuroPharma offers products and services including Trudhesa and POD Technology. Impel NeuroPharma operates in a competitive market with competitors including MannKind Corp, OptiNose, CraniUS, Alexza and Qnovia, among others.
- Headquarter Seattle, United States
- Employees 158
- Stage Public
- SectorsHealthcare
- Phone•••• ••••
- Website impelnp.com
- Social LinkedIn X
- Legal Name Impel Pharmaceuticals Llc
- Total Equity Funding$126.83M (USD)
in 19 rounds
- Latest Funding Round$7.5M (USD), Debt – Conventional
Mar 2021
- InvestorsKKR
& 7 more
- Employee Count158
Products & Services of Impel NeuroPharma
Impel NeuroPharma offers a comprehensive portfolio of products and services, including Trudhesa and POD Technology.
Nasal spray for acute migraine treatment with or without aura.
Proprietary system for optimized intranasal drug absorption.
Funding Insights of Impel NeuroPharma
Impel NeuroPharma has successfully raised a total of $126.83M across 19 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $7.5 million completed in March 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $126.83M
- Total Rounds 19
- Last Round Debt – Conventional — $7.5M
- First Round $305,364
(Jan 2010)
- Investors Count 8
Latest 10 of 19 funding rounds of Impel NeuroPharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2021 | $7.5M | Debt – Conventional | – | – | – |
| Dec 2018 | $67.5M | Series D | – | KKR, Norwest Venture Partners | |
| Dec 2016 | $21M | Series C | – | – | |
| Nov 2016 | $22.3M | Series C | – | VenBio, 5AM Ventures | – |
| Oct 2016 | $80,000 | Debt – Conventional | – | – | – |
| Sep 2016 | $80,000 | Debt – Conventional | – | – | – |
| Aug 2016 | $1.09M | Series B | – | – | – |
| Jul 2016 | $1.09M | Debt – Conventional | – | – | – |
| May 2016 | $1.5M | Grant | – | – | |
| Sep 2015 | $4M | Series B | – | – |
8 investors in total: 8 institutional.
Investors in Impel NeuroPharma
Impel NeuroPharma has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include KKR, NIH and Norwest Venture Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Multiple sectors are invested in by this private equity firm. | 1976 | kkr.com | New York, United States | |
Venture capital and growth equity firm providing investments and resources to entrepreneurs in various sectors. | 1961 | nvp.com | Menlo Park, United States | |
Venture capital and private equity firm | – | vivocapital.com | Palo Alto, United States | |
Venture capital fund backed incubator focused on the healthcare startups | – | 5amventures.com | San Francisco, United States | |
A life sciences investment firm focused on novel therapeutics is operated. | 2011 | venbio.com | San Francisco, United States | |
- | – | allianceofangels.com | - | |
Drug discovery services are provided to the biopharma sector. | 1887 | nih.gov | United States | |
3M is recognized as a global leader in innovative industrial and consumer solutions. | – | solutions.3m.com | United States |
Investor details for Impel NeuroPharma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Impel NeuroPharma
25 people are tracked at Impel NeuroPharma (5 in leadership, 10 in board & advisors, 10 in team); the tracked headcount is 158.
| Name | Role | Group |
|---|---|---|
Derek Troutman | West Area Sales Director | Leadership |
Leonard S. Paolillo | Chief Commercial Officer | Leadership |
Michael Malafronte | VP of Quality Assurance | Leadership |
Brian Phillips | Vice President Of Sales And Marketing | Leadership |
Gerald F. Penn | VP of Market Access & Trade | Leadership |
Timothy S. Nelson | Director | Board & advisors |
Aaron Royston | Director | Board & advisors |
Leslie S. Zun | Chair, Agitation Scientific Advisory Board | Board & advisors |
Greg Davis | Chair, Nasal Safety Review Committee | Board & advisors |
Mahendra G. Shah | Director | Board & advisors |
David Allison | Director | Board & advisors |
Ali Satvat | Director | Board & advisors |
Stewart J. Tepper | Chair, Migraine Scientific Advisory Board | Board & advisors |
Robert A. Hauser | Chair, Parkinson's Scientific Advisory Board | Board & advisors |
Robert Mittendorff | Director | Board & advisors |
Nicole O'Connell | Neurology Sales Representative | Team |
Beth Lydin | Accounting Manager | Team |
Kristy Nichols | Neuroscience Sales Specialist | Team |
Jeff Winé | Neurology Sales Specialist | Team |
Karen Bodin-Rincon | Neuroscience Specialist | Team |
5 more people are available in the full profile.
Complete people profiles for Impel NeuroPharma
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Impel NeuroPharma
4 dated milestones of Impel NeuroPharma across 13 years, from founding to its latest funding, stage changes and deals.
- Founded Impel NeuroPharma is founded.
- Funding First funding round of $305K.
- Funding Latest funding round, Debt – Conventional, of $7.5M.
- IPO Lists on the stock exchange (IPO).
Competitors of Impel NeuroPharma
Impel NeuroPharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as MannKind Corp, OptiNose, CraniUS, Alexza and Qnovia, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| mannkindcorp.com | 1991 | Los Angeles, United States | $50M | 322 | Developer of small-molecule drugs | |
| optinose.com | 2000 | Morrisville, United States | $120.5M | 132 | Developer of smart devices for nasal drug delivery | |
| craniustherapeutics.com | 2021 | Baltimore, United States | $20.5M | – | Drug delivery systems for brain diseases and disorders are developed. | |
| alexza.com | 2000 | Mountain View, United States | $97M | 72 | Developer of products for the treatment of acute and intermittent conditions | |
| qnovia.com | 2018 | Richmond, United States | $38.12M | – | Inhaled drug delivery devices are developed for pharmaceuticals. | |
| iconovo.se | 2013 | Lund, Sweden | $3.56M | – | Inhalation devices for medical applications are developed by Iconovo. | |
| aerami.com | 2010 | Durham, United States | $151.1M | – | Therapeutics for cardiopulmonary diseases are developed using inhaled therapies. | |
| nobhilltherapeutics.com | 2016 | Albuquerque, United States | $3.67M | – | Dry powder nebulizer is developed for targeted lung drug delivery. | |
| neonctech.com | 2008 | Los Angeles, United States | $18.74M | – | Drug delivery methods for brain cancer therapeutics are developed intranasally. |
Detailed competitors of Impel NeuroPharma
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Impel Neuropharma
Complete news archive for Impel NeuroPharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Impel NeuroPharma
10 companies that operate in the same segment as Impel NeuroPharma (Biopharma Outsourcing & Drug Delivery), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of integrated contract research development and manufacturing services | 2007 | Bengaluru, Karnataka, India | USD 35.74 M | USD 226.38 M | 1,820 | |
Drug discovery and development services are provided to biopharma sector. | 1993 | Hamburg, Hamburg, Germany | USD 25 M | USD 926.33 M | 4,830 | |
Drug discovery and development services for small molecules are provided. | 2003 | Beijing, China | USD 320 M | – | 476 | |
Suite solutions are provided for payers and healthcare providers. | 1998 | Princeton, New Jersey, United States | USD 255.15 M | USD 374.1 M | 4,490 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 | |
Pharmaceutical and biotechnology company | 2005 | Hyderabad, Telangana, India | USD 229.73 M | USD 726.15 M | 12,470 | |
Pharmaceutical products for treating multiple diseases are provided. | 1849 | New York, New York, United States | USD 8 M | USD 266.99 M | 1,770 | |
Provider of laboratory tests for physicians | 1969 | Burlington, Vermont, United States | – | USD 13.95 B | 70,000 | |
India's leading healthcare products distribution platform | 2018 | Mumbai, Maharashtra, India | USD 59.67 M | USD 702.49 M | 4,260 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Impel NeuroPharma
Impel NeuroPharma was founded in 2008 and raised its 1st funding round 2 years after it was founded.
Impel NeuroPharma is headquartered in Seattle, United States. It is registered at Seattle, Washington, United States.
Impel NeuroPharma is a funded company, having raised a total of $126.83M across 19 funding rounds to date. The company's 1st funding round was a Series B of $4M, raised on Jan 2010.
Impel NeuroPharma has 158 employees.
Impel NeuroPharma was founded in 2008 in Seattle, United States. Intranasal drug delivery technology is developed by the company for central nervous system diseases. Non-invasive Precision Olfactory Delivery (POD) nasal devices are utilized to create therapies targeting Alzheimers, migraine, and other CNS conditions. Various drugs, including biologics, are enabled for delivery directly to the brain through this approach. Operations focus on biotechnology within the pharmaceutical sector.
Impel NeuroPharma's top competitors include MannKind Corp, OptiNose and CraniUS.
Impel NeuroPharma offers Trudhesa and POD Technology.
Impel NeuroPharma has 8 investors. Key investors include KKR, NIH, Norwest Venture Partners, Vivo Capital, and 5AM Ventures.
Impel NeuroPharma operates through Impel Pharmaceuticals Llc.